Quest Diagnostics
0KSX.L
$182.45 -1.05%
Exchange: LSE | Sector: Healthcare | Industry: Medical Equipment Services
Q3 2024
Published: Oct 23, 2024

Earnings Highlights

  • Revenue of $2.49B up 8.4% year-over-year
  • EPS of $1.99 increased by 1% from previous year
  • Gross margin of 32.6%
  • Net income of 226.00M
  • "" -
0KSX.L
Company 0KSX.L

Executive Summary

Quest Diagnostics reported a solid QQ3 2024 with revenue of $2.488 billion, up 8.4% year over year and 3.8% quarter over quarter. Gross profit was $811 million, yielding a gross margin of approximately 32.6%, while EBITDA reached about $479 million and operating income was $330 million, translating to an operating margin of 13.3% and a net income of $226 million (net margin ~9.1%). The quarter benefited from healthy testing volumes and mix, but profitability was moderated by ongoing acquisition activity and related amortization and integration costs. The company generated free cash flow of $250 million and ended the period with $764 million in cash, while net debt stood at roughly $6.21 billion, reflecting a deliberate capital allocation strategy that included significant acquisitions (acquisitions net outflow of about $1.53 billion) and debt financing. Management commentary (not embedded in the provided transcript) typically emphasizes core diagnostic testing demand, streamlining operations, and disciplined capital allocation; investors should monitor organic growth, margin trajectory, integration of acquisitions, and the balance sheet as key drivers of medium-term value.

Key Performance Indicators

Revenue
Increasing
2.49B
QoQ: 3.80% | YoY: 8.41%
Gross Profit
Increasing
811.00M
32.60% margin
QoQ: 0.87% | YoY: 7.56%
Operating Income
Decreasing
330.00M
QoQ: -7.04% | YoY: -3.51%
Net Income
Increasing
226.00M
QoQ: -1.31% | YoY: 0.44%
EPS
Increasing
2.01
QoQ: -1.95% | YoY: 1.01%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 2,816.00 2.16 +13.2% View
Q2 2025 2,761.00 2.47 +15.2% View
Q1 2025 2,652.00 1.94 +12.1% View
Q4 2024 2,621.00 1.95 +14.6% View
Q3 2024 2,488.00 1.99 +8.4% View